Nearly 1 in 6 young patients on Ozempic, Saxenda and similar drugs developed a deficiency within a year—even as other research flags brain risks.
Semaglutide improved memory, muscle function and blood sugar in older mice—and its benefits exceeded those of calorie restriction alone, prompting human trials.
Real-world study shows GLP-1 medications may cut asthma attacks by 40% and COPD exacerbations by 20%, expanding their potential reach beyond diabetes and weight loss.
Swedish study of 15,000 patients finds semaglutide linked to 21% fewer psychiatric admissions; psychiatrists and lawsuits highlight mental health risk concerns.
A new generation of hair loss treatments could hit the market by 2027, drawing investor interest in a multi-billion-dollar opportunity.
New once-daily aleniglipron shows promising Phase II results, while Medicare expands coverage for existing GLP-1 drugs starting July 1.
Reports of a record-breaking pharma tie-up sent shares tumbling before a senior source denied the talks, exposing investor skepticism and strategic tensions.
As Eli Lilly surges and Amazon Pharmacy enters the fray, Novo Nordisk fights back with global expansion and deep cost cuts.
Generic versions of a new daily pill could cost as low as $5 per person per year, but access in Latin America remains uncertain.